Selank vs Semax
A comparison of Selank and Semax as Russian neuropeptides, covering mechanism differences, anxiolytic vs. cognitive focus, evidence context, and administration research.
A comparison of Selank and Semax as Russian neuropeptides, covering mechanism differences, anxiolytic vs. cognitive focus, evidence context, and administration research.
Overview
Selank and Semax are both Russian-developed neuropeptides that have received regulatory approval in Russia for neurological and psychiatric applications, but they are studied for different primary mechanisms and research questions. Selank is more commonly framed as an anxiolytic compound, while Semax is more often discussed in neuroprotective and cognitive enhancement contexts.
Mechanism Comparison
Selank is a synthetic heptapeptide analog of the endogenous tuftsin molecule, studied for modulation of IL-6, enkephalins, and anxiolytic signaling without benzodiazepine receptor activity. Semax is a synthetic analog of the ACTH 4-7 fragment, studied for BDNF upregulation, neuroprotective effects following ischemia, and cognitive enhancement in experimental settings.
Dosing and Protocol Comparison
Both compounds are commonly studied via intranasal administration, which is the primary route in Russian clinical research. This makes them somewhat unusual in the research peptide landscape, where subcutaneous injection is the more standard route. Intranasal delivery is discussed as enabling direct CNS exposure, and most published protocols for both compounds reflect this route.
Evidence Comparison
Both compounds have more published literature in Russian-language journals than in English-indexed databases, which makes direct evidence review more difficult for Western researchers. Semax has been studied more extensively in stroke and neuroprotection models, while Selank evidence is more concentrated in anxiety and immune-regulation research. PeptaBase includes both with their available citation context.